DelveInsight’s, “Aminopeptidase Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Aminopeptidase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Aminopeptidase Inhibitors: Overview
Aminopeptidases, which are widely distributed in nature, are one of the two major subclasses of the exopeptidases, proteolytic enzymes that remove amino acids from the termini of peptides and proteins (the other being the carboxypeptidases). As the name indicates, the aminopeptidases attack their substrates exclusively from the amino terminal end. Aminopeptidase A (APA), also known as a glutamyl aminopeptidase and CD249, cleaves the N-terminal residue of AngII to form Ang-(2-8), also known as angiotensin-III (AngIII). Methionine aminopeptidase (MetAP) catalyzes the hydrolytic cleavage of the N-terminal methionine from newly synthesized polypeptides.
The companies and academics are working to assess challenges and seek opportunities that could influence Aminopeptidase Inhibitors R&D. The therapies under development are focused on novel approaches for Aminopeptidase Inhibitors.
This segment of the Aminopeptidase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Aminopeptidase Inhibitors Emerging Drugs
Firibastat: Quantum Genomics
The firibastat (originally named QGC001) product is the first BAPAI candidate-drug selected by Quantum Genomics. The firibastat product is a prodrug that delivers in the brain the EC33 product, a selective and specific inhibitor of Aminopeptidase A, thus preventing the production of Angiontensin III in the brain. Due to its unique action mechanism, firibastat represents an alternative therapeutic approach which can interfere with the mechanisms involved in the genesis and control of blood pressure in hypertensive patients, especially those with a particular hormonal profile, characterized by a low renin concentration and a high vasopressin concentration (Low Renin High Vasopressin (LRHV) profile). Firibastat and its therapeutic use are strongly protected by several families of patents ensuring an industrial protection until 2033 without taking into consideration the potential additional protection certificates.
APL-1202: Asieris Pharmaceuticals
APL-1202 is an innovative oncology drug developed by Asieris Pharmaceuticals over the past decade after in-licensing the patented technology from Johns Hopkins University in the United States. As the first-in-class oral and reversible methionine aminopeptidase 2 (MetAP2) inhibitor to enter a pivotal/phase III clinical trial, APL-1202 is the world’s first oral targeted therapy for non-muscle invasive bladder cancer (NMIBC) under a pivotal/phase III clinical trial. At the same time, APL-1202 is also being developed for preoperative neoadjuvant treatment of muscle invasive bladder cancer (MIBC).
Further product details are provided in the report……..
This segment of the report provides insights about the different Aminopeptidase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the Aminopeptidase Inhibitors. The companies which have their Aminopeptidase Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Quantum Genomics.
DelveInsight’s report covers around 8+ products under different phases of clinical development like
Aminopeptidase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Aminopeptidase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aminopeptidase Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Aminopeptidase Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Aminopeptidase Inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Firibastat: Quantum Genomics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
PL 37: Pharmaleads
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
M 8891: EMD Serono
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
SDX 7195: SynDevRx, Inc
Drug profiles in the detailed report…..
Inactive Products
Aminopeptidase Inhibitors Key Companies
Aminopeptidase Inhibitors Key Products
Aminopeptidase Inhibitors- Unmet Needs
Aminopeptidase Inhibitors- Market Drivers and Barriers
Aminopeptidase Inhibitors- Future Perspectives and Conclusion
Aminopeptidase Inhibitors Analyst Views
Aminopeptidase Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Aminopeptidase Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Aminopeptidase Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Quantum Genomics
• Asieris Pharmaceuticals
• Pharmaleads
• EMD Serono
• SynDevRx, Inc
• Larimar Therapeutics
